新型冠状病毒肺炎防疫期间慢性病毒性肝炎患者的管理

李亮亮; 于岩岩

doi:10.3969/j.issn.1001-5256.2020.05.010

新型冠状病毒肺炎防疫期间慢性病毒性肝炎患者的管理

DOI: 10.3969/j.issn.1001-5256.2020.05.010

1. 北京大学第一医院超声医学科
2. 北京大学第一医院感染疾病科

基金项目:

“十三五”国家科技重大专项基金资助项目（2017ZX10202202-001-006）；

详细信息

中图分类号: R512.6
计量
- 文章访问数: 1063
- HTML全文浏览量: 74
- PDF下载量: 134
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-05
- 出版日期: 2020-05-20

Management strategies for patients with chronic viral hepatitis during the coronavirus disease 2019 epidemic

Department of Ultrasonic Medicine,Peking University First Hospital

Research funding:

摘要

摘要:
在我国严重的新型冠状病毒肺炎疫情期间,部分慢性病毒性肝炎患者就医用药出现困难。介绍了特殊时期医疗机构对慢性病毒性肝炎患者的管理策略,包括采用长处方并提升患者的依从性、互联网远程出诊、社区卫生服务中心参与管理、药剂师参与指导患者用药、护士参与提升患者自我管理能力。同时患者应加强生活方式的自我管理并做好外出防护。认为在医患双方共同努力下,慢性病毒性肝炎患者在特殊时期会得到妥善的管理。
- 新型冠状病毒肺炎 /
- 肝炎,病毒性,人 /
- 病人医护管理
Abstract:
During the severe epidemic of coronavirus disease 2019(COVID-19) in China, some patients with chronic viral hepatitis have difficulties in attending the hospital and getting medical treatment. This article introduces the management strategies for patients with chronic viral hepatitis in medical institutions, including long prescription to improve patients' compliance, long-distance online outpatient service,participation of community health service centers in management, medication guidance for patients by pharmacists, and nurses' participation in improving patients' self-management ability. At the same time, patients should also strengthen the self-management of life style and take protective measures when going out. With the efforts of both doctors and patients, proper management of patients with chronic viral hepatitis will be achieved during this special period.
- coronavirus disease 2019 /
- hepatitis,viral,human /
- patient care management

HTML全文

参考文献(35)

[1] WU Z, MCGOOGAN JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China:Summary of a report of 72 314 cases from the Chinese center for disease control and prevention[J]. JAMA,2020.[Online ahead of print]

[2] Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on epidemiological characteristics of novel coronavirus pneumonia(COVID-19)[J]. Chin J Viral Dis, 2020, 10(2):81-87.(in Chinese）中华预防医学会新型冠状病毒肺炎防控专家组．新型冠状病毒肺炎流行病学特征的最新认识[J]．中国病毒病杂志，2020, 10(2):81-87.

[3] WONG W, LO YR, JIANG S, et al. Improving the hepatitis cascade:Assessing hepatitis testing and its management in primary health care in China[J]. Fam Pract, 2018, 35(6):731-737.

[4] Chinese Society of Hepatology and Chinese Society of Infection Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12):2670-2686.(in Chinese）中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南（2019年版）[J]．临床肝胆病杂志，2019, 35(12):2670-2686.

[5] Chinese Society of Infection Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2019 version)[J]. J Clin Hepatol, 2019, 35(12):2648-2669.(in Chinese）中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南（2019年版）[J]．临床肝胆病杂志，2019, 35(12):2648-2669.

[6] GHOURI YA, MIAN I, ROWE JH. Review of hepatocel ular carcinoma:Epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 16(1):1-31.

[7] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.

[8] GO H, TANAKA M, YAMAMOTO-MITANI N, et al. Medication adherence among patients with chronic hepatitis receiving antiviral treatment[J]. Gastroenterol Nurs, 2019, 42(2):140-149.

[9] LI T, LIN QY, HUANG T, et al. Short-term effect of chronic disease patients with long-term prescription policy on the healthcare quality of contracted patients and policy recommendations[J]. Chin Gen Prac, 2017, 20(25):3084-3087.(in Chinese）李婷，林其意，黄涛，等．慢性病长处方政策对签约患者医疗质量的短期影响及政策建议[J]．中国全科医学，2017, 20(25):3084-3087.

[10] XU K, LIU LM, FARAZI PA, et al. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B[J].Glob Health Action, 2018, 11(1):1433987.

[11] XU ZJ, QI L, CAI BY, et al. New method for chronic disease management by using social media platform in community hospitals[J]. Chin J Health Educ, 2017, 33(10):957-959.(in Chinese）徐志杰，戚麟，蔡博宇，等．社区医院利用社交媒体平台开展慢性病管理的新思路[J]．中国健康教育，2017, 33(10):957-959.

[12] ANDREONE P, DI MARCO V, GAETA GB, et al. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection:Assessment of an Italian focus group[J]. Dig Liver Dis, 2019, 51(7):915-921.

[13] O’ LEARY DA, CROPP E, ISAAC D, et al．“B in IT”-a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool[J]. Hepatol Med Policy, 2018, 3(1):1-10.

[14] LIU S, HUANG J, FAN J, et al. Fluctuating operation development index of community health service centres in the Pudong new area of Shanghai:A continuous investigation[J]. Int J Health Plann Manage, 2019, 34(1):e679-679, e693.

[15] DONG JL, HAN XL, LI J, et al. The clinical application of chronic contagious liver disease management mode[J]. J Beijing Med, 2016, 38(9):956-959.(in Chinese）董金玲，韩笑乐，李娟，等．慢性传染性肝病管理模式的临床应用[J]．北京医学，2016, 38(9):956-959.

[16] SUN X, LI Y, LIU S, et al. Enhanced performance of community health service centers during medical reforms in pudong new district of Shanghai, China:A longitudinal survey[J].PLoS One, 2015, 10(5):e0125469.

[17] SHIHA G, METWALLY AM, SOLIMAN R, et al. An educate,test, and treat programme towards elimination of hepatitis C infection in Egypt:A community-based demonstration project[J]. Lancet Gastroenterol Hepatol, 2018, 3(11):778-789.

[18] SU J,YANG Y,YI CT. Practice and reflection about two-way referral of community health service center[J]. Chin Hosp Manage, 2016, 36(5):74-75.(in Chinese）苏瑾，杨恽，易春涛．社区卫生服务中心双向转诊的实践与思考[J]．中国医院管理，2016, 36(5):74-75.

[19] FELGER JC, COLE SW, PACE TW, et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-αtreatment:Relationship with depression and fatigue[J]. Psychol Med, 2012, 42(8):1591-1603.

[20] de SEVILLA MÁCF, GALLEGOU'BEDA M, HEREDIA BENITO M, et al. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals[J]. Int J Clin Pharm, 2019, 41(2):488-495.

[21] GOMES LO, TEIXEIRA MR, ROSA J, et al. The benefits of a public pharmacist service in chronic hepattis C treatment:The real-life results of sofosbuvir-based therapy[J]. Res Social Adm Pharm, 2020, 16(1):48-53.

[22] HAYAT K, LI P, ROSENTHAL M, et al. Perspective of community pharmacists about community-based antimicrobial stewardship programs. A multicenter cross-sectional study from China[J]. Expert Rev Anti Infect Ther, 2019, 17(12):1043-1050.

[23] QIN SB, ZHANG XY, FU Y, et al. The impact of the clinical pharmacist-led interventions in China:A systematic review and Meta-analysis[J]. Int J Clin Pharm, 2020.[Online ahead of print]

[24] XU P, HU YY, YUAN HY, et al. The impact of a training program on clinical pharmacists on pharmacy clinical services in a tertiary hospital in hunan China[J]. J Multidiscip Healthc,2019, 12:975-980.

[25] XIAO N, WANG JW. Thinking of pharmacists introducing big data:Innovation of chronic disease management mode[J].China Pharm, 2016, 27(22):3158-3160.(in Chinese）肖宁，王家伟．药师将互联网大数据引入慢病管理模式的创新思考[J]．中国药房，2016, 27(22):3158-3160.

[26] CUI Y, MORIYAMA M, CHAYAMA K, et al. Efficacy of a selfmanagement program in patients with chronic viral hepatitis in China[J]. BMC Nurs, 2019, 18:44.

[27] BOULHOSA RS, OLIVEIRA LP, JESUS RP, et al. The impact of nutritional supplementation on quality of life in patients infected with hepatitis C virus[J]. J Hum Nutr Diet, 2013, 26(Suppl 1):7-15.

[28] EGUCHI Y, MIZUTA T, ISHIBASHI E, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation[J]. Liver Int, 2009, 29(2):213-220.

[29] PATTULLO V, DUARTE-ROJO A, SOLIMAN W, et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C[J]. Liver Int, 2013, 33(3):410-419.

[30] IWANE S, MIZUTA T, KAWAGUCHI Y, et al. Impact of body weight reduction via diet and exercise on the anti-viral effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with insulin resistance:A randomized controlled pilot trial[J]. Intern Med, 2015, 54(24):3113-3119.

[31] SUBLETTE VA, DOUGLAS MW, MCCAFFERY K, et al. Psychological, lifestyle and social predictors of hepatitis C treatment response:A systematic review[J]. Liver Int, 2013, 33(6):894-903.

[32] KIM K, CHOI S, PARK SM. Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection:A Korean population-based cohort study[J]. JAMA Oncol, 2018, 4(5):737-739.

[33] IIDA-UENO A, ENOMOTO M, TAMORI A, et al. Hepatitis B virus infection and alcohol consumption[J]. World J Gastroenterol, 2017, 23(15):2651-2659.

[34] MAGRI MC, NUNES A, DANTAS BP, et al. Meta-analysis of the prevalence of HBV infection among alcohol users worldwide[J]. Alcohol Alcohol, 2020, 55(2):136-143.

[35] CHUANG SC, LEE YC, HASHIBE M, et al. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer:A meta-analysis[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(5):1261-1268.

施引文献

资源附件(0)

访问统计